U.S. Building Stock News

If you are wondering whether Expeditors International of Washington is still worth buying after a strong run, or if the easy money has already been made, you are not alone. That is exactly what we are going to unpack here. The stock has climbed 2.4% over the last week, 9.5% over the past month, and is up 37.8% year to date. It has gained 30.3% over the last year, 45.5% over three years, and 70.1% over five years, so the market clearly likes the story so far. Recent investor attention has...

Fresh insider buying at MGM Resorts International (MGM), led by major holder IAC snapping up roughly 1.1 million shares, has put the spotlight back on the casino giant's digital and sports betting ambitions. See our latest analysis for MGM Resorts International. The fresh insider buying comes on the back of a solid run, with MGM’s share price delivering a low double digit year to date return and a mid single digit total shareholder return over the past year. This suggests momentum is quietly...

A major brokerage just reiterated its upbeat view on Global-E Online (GLBE), highlighting the company’s leading role in cross border e commerce, its solid balance sheet, and its long runway for growth. See our latest analysis for Global-E Online. Even with this upbeat call, Global-E Online’s share price has been volatile. A 1 month share price return of 8.45% and a 3 year total shareholder return of 90.41% point to long term momentum despite a weak year to date patch. If you like the growth...

If you are wondering whether National Fuel Gas is still worth considering after its strong run, or if the easy money has already been made, you are not alone. The stock has climbed to around $82.40, up 1.1% over the last week, 1.7% over the last month, and 34.3% year to date, with a 39.1% gain over the past year and 133.9% over five years. That kind of steady outperformance has been supported by a favorable backdrop for US natural gas infrastructure and storage, as investors look for...

Wondering if McKesson is still a buy after such a powerful run, or if the easy money has already been made? This article will walk through the numbers with you, step by step. The stock just closed around $823.01, up 3.1% over the last week but down 2.3% over the past month, while still showing gains of 45.4% year to date and 45.0% over the last year, and 122.4% and 394.6% over the past 3 and 5 years. Investors have been digesting a steady stream of news around McKesson's role in...

Astrana Health (ASTH) just got a fresh spotlight from Needham, which kicked off coverage by leaning into the company’s push toward value based care and full risk deals as a central long term growth story. See our latest analysis for Astrana Health. The mixed reaction to Needham’s upbeat initiation, combined with a recent earnings stumble and visible insider activity, helps explain why Astrana’s 30 day share price return is positive while its year to date share price return and one year total...

Crane NXT (CXT) has quietly slipped over the past month, but the underlying business is still growing, with revenue and earnings both moving in the right direction despite recent share price weakness. See our latest analysis for Crane NXT. That recent 1 month share price return of negative 15.16 percent, and a 1 year total shareholder return of negative 16.55 percent, suggests sentiment has become more cautious even as the business reports steady top and bottom line growth. If this kind of...

In mid-December 2025, Charles Schwab rolled out extensive enhancements across Schwab.com, Schwab Mobile and thinkorswim®, while also adding 17 new futures products and continuing to expand its nearly 400-branch network to support a surge in retail trading activity. These upgrades, including extended-hours valuation views, deeper fundamental data and more granular portfolio management tools, suggest Schwab is trying to tighten the link between higher client engagement and the firm’s already...

Many investors are asking whether Molson Coors Beverage at around $47.67 is a value opportunity or a value trap, and this breakdown is designed to provide a clearer perspective. The stock has bounced 5.4% over the last week and 2.6% over the past month, even though it is still down about 16.7% year to date and 16.6% over the last year. This pattern suggests sentiment may be shifting from overly pessimistic toward more cautious optimism. Recently, investors have been reacting to a mix of...

Alexandria Real Estate Equities recently cut its quarterly dividend by 45%, announced a new US$500 million share repurchase authorization after completing a prior US$258.25 million buyback, and disclosed the upcoming resignation of long‑time executive Daniel J. Ryan for personal and health reasons. These actions come as the company confronts multiple securities class action lawsuits tied to its Long Island City property, following weaker third‑quarter results, an impairment charge, and...

If you are wondering whether Starbucks at around $85 is a bargain or a value trap, you are not alone. This breakdown unpacks that question in detail. The stock has bounced about 3.8% over the last week and 0.7% over the last month, but it is still down roughly 7.3% year to date and 4.8% over the last year. This suggests the market is still undecided on its long term direction. Recent headlines have focused on Starbucks navigating shifting consumer spending, ongoing unionization efforts in...

ImmunityBio (IBRX) just cleared a big regulatory hurdle in Europe, with the EMA recommending conditional marketing authorization for its bladder cancer therapy Anktiva plus BCG in BCG unresponsive non muscle invasive disease. See our latest analysis for ImmunityBio. The EMA recommendation has come after a volatile stretch for ImmunityBio, with a 1 month share price return of 6.73 percent but a 1 year total shareholder return of negative 21.55 percent. This suggests optimism is rebuilding from...

Wondering if Union Pacific at around $240 a share is still a buy or if the value has already been priced in? This breakdown will walk you through what the market may be missing. After a steady climb with the stock up 3.8% over the last week, 7.8% over the past month, and 7.1% over the last year, investors are starting to question whether this momentum signals durable growth or creeping overvaluation. Recently, the stock has been moving on improving freight volume trends across the U.S. rail...

Wondering if Trip.com Group is still a smart way to play the travel recovery, or if most of the upside is already priced in? Let us unpack what the current share price is really implying about future growth. The stock has climbed 10.2% year to date to around $71.39, but it is still down 3.9% over the last year and roughly flat over the last month, suggesting investors are undecided about the next leg of the story. Sentiment has been shaped by ongoing recovery in global travel demand and...

Qualys (QLYS) has drifted slightly lower over the past week, even though the stock is still up over the past 3 months and year to date. That mix makes the current setup interesting. See our latest analysis for Qualys. That recent dip comes after a solid run, with a 90 day share price return of 9.6 percent and a three year total shareholder return of 27.4 percent, suggesting that momentum is still broadly positive despite short term volatility. If Qualys has you rethinking your exposure to...

Stewart Information Services (STC) just wrapped up a sizable equity raise, selling 1.9 million shares at a discount to bring in roughly $129 million, and potentially more if underwriters exercise their option. See our latest analysis for Stewart Information Services. The discounted raise comes after a busy stretch that includes a major acquisition of Mortgage Contracting Services and a conference appearance. The share price return has still climbed meaningfully this year, while multiyear...

Merck (MRK) just picked up a meaningful catalyst in Europe, with regulators recommending a broader approval for its pulmonary arterial hypertension drug Winrevair, a move that could gradually shift expectations for the stock. See our latest analysis for Merck. The Winrevair update lands after a solid run in the stock, with a roughly 24 percent 3 month share price return and a 5 year total shareholder return of about 55 percent. This suggests momentum is still building rather than fading at...

In early December 2025, Energy Transfer highlighted progress on nearly US$10.00 billion of growth projects, including new Permian pipelines and its Lake Charles LNG export development, supported by about US$6.20 billion in year-to-date cash generation and plans for 3% to 5% annual distribution increases. This combination of large-scale expansion and a targeted distribution growth framework points to a company leaning on financial flexibility to balance reinvestment with higher income...

In recent days, Bloom Energy has faced renewed pressure as concerns about delayed AI data center investments at partners like Oracle and broader doubts over the pace of AI infrastructure spending have weighed on sentiment, despite the company delivering multiple quarters of record revenue and margin improvement. These developments highlight how Bloom’s fortunes are increasingly tied to the timing and reliability of hyperscaler capital spending decisions, even as it secures large agreements...

Atkore (ATKR) is back on investors radar after fresh commentary highlighted how its dense U.S. manufacturing network and embedded digital design tools are supporting margins even as PVC spreads drift toward more normal levels. See our latest analysis for Atkore. Those fundamentals are coming into focus against a choppy backdrop, with the share price at $64.58 and a year to date share price return of minus 20.69 percent. The one year total shareholder return of minus 22.13 percent highlights...

W. R. Berkley (WRB) just paired its regular quarterly payout with a meaningful special dividend, sending a clear signal about balance sheet strength and management confidence in cash generation for long term shareholders. See our latest analysis for W. R. Berkley. Those regular and special dividends land against a backdrop where the latest share price of $69.1 sits below recent highs. Yet W. R. Berkley still posts a solid year to date share price return and an impressive multi year total...

If you are wondering whether GXO Logistics is actually worth its current share price, or if the recent excitement has left it looking a bit stretched, you are not alone. That is exactly what we are going to unpack here. Despite a small dip of about 1.1% over the last week, the stock is still up roughly 5.7% over the past month and 21.5% year to date, which suggests that investors see something to like in its long term story. Some of that optimism has been driven by ongoing enthusiasm around...

If you are wondering whether JPMorgan Chase is still a buy after its huge run, you are not alone. This article is going to unpack whether the current price really makes sense. The stock has climbed 1.5% over the last week, 5.4% over the past month, and is now up an impressive 33.3% year to date, with a 36.4% gain over the last year and almost tripling over three and five years. Much of this strength has been underpinned by JPMorgan's role as a bellwether for the US banking sector, as...

Terns Pharmaceuticals (TERN) just paired upbeat CARDINAL trial data for its CML candidate TERN-701 with aggressive financing moves, including a $650 million follow on equity raise, reshaping both its balance sheet and growth runway. See our latest analysis for Terns Pharmaceuticals. The CARDINAL data and follow on raises land on top of a huge run, with a roughly 95 percent 1 month share price return and a 547 percent 1 year total shareholder return signaling powerful, still building momentum...